Amicus Therapeutics: Q4 Earnings Snapshot
2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing...
PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold ® (migalastat)...
NEW YORK , Feb. 2, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...
Shareholders should contact the firm as there may be limited time to enforce your rights.
Shareholders should contact the firm as there may be limited time to enforce your rights.
NEW YORK , Jan. 7, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars...
Shareholders should contact the firm as there may be limited time to enforce your rights.
Shareholders should contact the firm as there may be limited time to enforce your rights.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Amicus Therapeutics...